Autoimmune thyroid disease following treatment with alemtuzumab for multiple sclerosis

Alemtuzumab, an anti-CD52 monoclonal antibody, is effective in the treatment of relapsing–remitting multiple sclerosis (RRMS). Common adverse effects include the development of autoimmune diseases, and Graves’ disease is one of the most frequent presentations. We report here a case of alemtuzumab-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Alamo, Angela, Condorelli, Rosita A, La Vignera, Sandro, Calogero, Aldo E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458661/
https://www.ncbi.nlm.nih.gov/pubmed/30968726
http://dx.doi.org/10.1177/2058738419843690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6458661/
https://www.ncbi.nlm.nih.gov/pubmed/30968726
http://dx.doi.org/10.1177/2058738419843690

Ejemplares similares